Shire’s Hemophilia Gene Therapy Boosted by Orphan Drug Designation

The FDA has granted orphan drug designation to Shire’s hemophilia A gene therapy, giving it the boost it needs to catch up with others in the field.

Shire specializes in the development of drugs for rare diseases, including hemophilia A – a bleeding disorder caused by a lack of clotting factor VIII activity in the blood. The company’s gene therapy candidate, SHP654, will deliver a functional copy of factor VIII or IX that will allow the body to begin producing a constant level of the factor. This news makes Shire a competitor in a field expected to be worth $25B (€21B) by 2024, which has so far been led by Roche and Spark Therapeutics.

In July, Roche announced the results of a Phase III trial investigating its monoclonal antibody, emicizumab, during which it reduced the bleed rate by 87%. US biotech, Spark, reported preliminary Phase I/II results for its gene therapy approach in August. Its candidate, SPK-8011, reduced the annual bleeding rate of ten patients by 96%. UniQure has focused on hemophilia B but is working on a gene therapy for hemophilia A at the preclinical stage.


Image – Ramona Kaulitzki / shutterstock.com

Previous post

British Researchers Develop Clever Nanoparticles to Kill Cancer Cells

Next post

Meet John Beadle, the Serial Entrepreneur with the Key to Oncolytic Viruses

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.